Biotechnology industries
Sangamo BioSciences, Inc. (NASDAQ:SGMO) has teamed up with Pfizer Inc to develop novel technologies for protein production. Under the agreement, Pfizer will fund research at Sangamo's facilities, and the company will utilize its proprietary zinc finger DNA binding protein (ZFP) technology to create enhanced cell lines for
Pharmaceutical industry
Researchers at Epigenomics, a molecular-diagnostics company, have successfully identified a set of DNA methylation biomarkers that closely correlate with prostate cancer aggressiveness. This breakthrough was made possible through a proprietary technology that uses DNA methylation markers to predict the likelihood of prostate cancer progression. The identified biomarkers also show a
Pharmaceutical industry
Dia-B Tech, an Australian-based medical research company, has sparked interest from global pharmaceutical companies for its potential diabetes treatments. The company, which listed on the Australian Stock Exchange today, is being courted by major players for partnerships or licensing deals. Its project, led by Professor Paul Zimmet, has been approached
Pharmaceutical industry
Maxim Pharmaceuticals, Inc., has made a significant breakthrough in cancer research with its proapoptotic cancer therapeutic candidate, MPC-6827. Developed in partnership with Myriad Genetics, Inc., MPC-6827 has shown promising results in preclinical studies, demonstrating better activity than current standard-of-care chemotherapy in xenograft models of various cancers. The compound's
Pharmaceutical industry
MorphoSys AG has achieved a significant milestone in the development of its HuCAL technology, as its partner GPC Biotech AG receives regulatory clearance to conduct a phase 1 clinical trial with an anticancer antibody generated using HuCAL. This trial represents the first time a HuCAL-derived antibody will enter clinical trials
Biotechnology industries
The US market's current influenza vaccine shortage created by Chiron's manufacturing problems has led to a significant increase in funding for biotechnology companies developing new vaccines. Local player BioDiem is making inroads in the area after announcing its first milestone payment from Nobilon, a subsidiary of
Biotechnology industries
V.I. Technologies, Inc. (VITX) has secured a significant influx of capital through a private placement of its common stock and warrants, totaling $20 million. The funding, led by Great Point Partners LLC, marks a major milestone for the biotechnology company, which is developing anti-infective products. The private placement is
Biotechnology industries
ConjuGon, a biotechnology company focused on developing new treatments for antibiotic-resistant bacterial infections, has strengthened its board of directors with the appointment of Guillermo Herrera. Herrera brings over two decades of experience in the pharmaceutical industry, including senior leadership positions at Abbott Laboratories. His expertise will be crucial in guiding
Biotechnology industries
The National Cancer Institute (NCI) and Alfacell Corporation have entered into a collaboration to pursue the development of RN321, an anti-CD22/RNase immunoconjugate, a promising anti-cancer therapeutic agent. RN321 combines a B-cell specific monoclonal antibody with Onconase, Alfacell's lead investigational drug candidate, creating a potent cytotoxic agent. This
Pharmaceutical industry
Teva Pharmaceutical Industries Ltd. has reported a significant surge in earnings, escaping the difficulties faced by other generic drug manufacturers. This positive news comes amidst a challenging market situation. Meanwhile, Genzyme Corp. has announced an agreement with Wyeth Pharmaceuticals to acquire the sales and marketing rights to Synvisc in the
Pharmaceutical industry
ParAllele BioScience, a South San Francisco-based genetic discovery company, has entered into a collaboration with Novartis Pharma AG to discover genetic variations associated with coronary artery disease. This disease, which affects 13 million people in the United States, is the leading cause of death for both men and women. The
Pharmaceutical industry
The biotechnology sector has become increasingly important for the pharmaceutical industry in recent years, with traditional pharmaceutical groups turning to biotech firms to help bolster their early-stage development programs. According to a study by Ernst & Young, the biotechnology sector owns about half the drugs in clinical development. As a
